Thermo Fisher Scientific has formed a strategic partnership with Megaware, a life science technology organisation, to deliver a new bioanalysis solution and joint support services for pharmaceutical, biotech and contract research organisations (CROs).
Under the terms of the collaboration, Thermo Fisher and Megaware will jointly sell, support and market a new comprehensive end-to-end software solution which provides bioequivalence functionality on a single platform to help speed up and manage clinical trials.
Rapid market growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications). A unified software solution will aggregate disparate software systems for organisations that demand tools to speed service and management of this critical and regulated IPO.
‘The market for bioequivalence studies in India and the Far East is growing rapidly,’ said Dave Champagne, vice president and general manager of informatics for Thermo Fisher.
The two companies will work together closely to target the market for bioanalysis/equivalence studies, initially in India and thereafter across the Far East and other markets.
